Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 23400963)

1.

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors.

Dong P, Liu ZW, Li XD, Li YH, Yao K, Wu S, Qin ZK, Han H, Zhou FJ.

Med Oncol. 2013 Mar;30(1):494. doi: 10.1007/s12032-013-0494-y. Epub 2013 Feb 12.

PMID:
23400963
2.

[Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors].

Dong P, Liu ZW, Li XD, Wu S, Li YH, Yao K, Qin ZK, Han H, Zhou FJ.

Zhonghua Wai Ke Za Zhi. 2013 Mar;51(3):256-60. Chinese.

PMID:
23859330
3.

Clinical outcomes in patients with stage I non-seminomatous germ cell cancer.

Lv ZJ, Wu S, Dong P, Yao K, He YY, Gui YT, Zhou FJ, Liu ZW, Cai ZM.

Asian J Androl. 2013 Jul;15(4):558-63. doi: 10.1038/aja.2013.16. Epub 2013 May 20.

4.

[Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].

Liu ZW, Zhou FJ, Han H, Qin ZK, Yu SL, Li YH, Ye YL, Teng XY.

Ai Zheng. 2008 Dec;27(12):1302-6. Chinese.

PMID:
19079998
5.

Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?

Divrik RT, Akdoğan B, Ozen H, Zorlu F.

J Urol. 2006 Oct;176(4 Pt 1):1424-29; discussion 1429-30.

PMID:
16952649
6.

Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.

Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J.

J Urol. 2005 Aug;174(2):557-60; discussion 560.

PMID:
16006891
7.

Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy.

Kobayashi K, Saito T, Kitamura Y, Nobushita T, Kawasaki T, Hara N, Takahashi K.

Diagn Pathol. 2013 Apr 8;8:57. doi: 10.1186/1746-1596-8-57.

8.
9.

Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Stephenson AJ, Sheinfeld J.

Curr Treat Options Oncol. 2005 Sep;6(5):367-77. Review.

PMID:
16107240
10.

Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.

Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel Huinink WW, van de Vijver M, Witjes JA, Horenblas S.

Urology. 2002 Jun;59(6):923-9.

PMID:
12031382
11.

What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?

Ekenel M, Keskin S, Sanli Ö, Bavbek S, Tunç M, Ander H, Ozcan F, Kiliçaslan I, Başaran M.

Clin Genitourin Cancer. 2012 Sep;10(3):185-9. doi: 10.1016/j.clgc.2012.04.002. Epub 2012 Jun 7.

PMID:
22682983
12.

Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?

Powles T.

Hematol Oncol Clin North Am. 2011 Jun;25(3):517-27,viii. doi: 10.1016/j.hoc.2011.03.013. Review.

PMID:
21570606
13.

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group.

J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Epub 2008 May 5. Erratum in: J Clin Oncol. 2010 Mar 10;28(8):1439. Dosage error in article text.

14.

Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis.

Pizzocaro G, Zanoni F, Salvioni R, Milani A, Piva L, Pilotti S.

J Urol. 1987 Dec;138(6):1393-6.

PMID:
2824862
15.

Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment.

Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornák M.

Eur Urol. 1998;33(6):562-6.

PMID:
9743698
17.

Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.

Klepp O, Olsson AM, Ous S, Nilsson S, Høisaether PA, Tveter K.

Scand J Urol Nephrol. 1991;25(3):179-90.

PMID:
1658924
18.

Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.

Fléchon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP.

BJU Int. 2010 Sep;106(6):779-85. doi: 10.1111/j.1464-410X.2009.09175.x. Epub 2010 Jan 19.

PMID:
20089110
19.

Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.

Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J.

Urology. 2012 May;79(5):1079-84. doi: 10.1016/j.urology.2011.11.090. Epub 2012 Mar 23.

PMID:
22446341
20.

Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.

Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.

J Clin Oncol. 2005 Apr 20;23(12):2781-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk